Hyderabad-based biopharmaceutical company Suven Life Sciences Limited has secured product patents for four of its new chemical entities (NCEs) in China, Mexico and New Zealand. The patents are valid through 2028.
The NCEs are useful in treatment of disorders associated with neurodegenerative diseases like Alzheimer's, attention deficient hyperactivity disorder, Huntington's, Parkinson and schizophrenia.
With the new patents, Suven has a total of 10 patents granted by China and 14 each granted by Mexico and New Zealand.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena and are being developed for cognitive disorder with high unmet medical need", Suven chief executive officer, Venkat Jasti, stated in a press release.
